Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism

Haematologica

Volumn 100, Issue 2, 2015, Pages 188-193

  Der Van Hulle, Tom ^a   Tan, Melanie ^a   Den Exter, Paul L ^a   Van Roosmalen, Mark J G ^a   Der Van Meer, Felix J M ^a   Eikenboom, Jeroen ^a   Huisman, Menno V ^a   Klok, Frederikus A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; D DIMER; ORAL CONTRACEPTIVE AGENT;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RECURRENCE RISK; TESTIS CANCER; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84964260523     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112896     Document Type: Article

References (16)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e494S.
2. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous throm-boembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336(6):393-398.
3. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Diagnostiek, Preventie en Behandeling van Veneuze Trombo-embolie en Secundaire Preventie Arteriële Trombose. 2009:111-116.
4. van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med. 2003;163(11):1285-1293.
5. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboem-bolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
6. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423-428.
7. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost. 2013;11(3):412-422.
8. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihe-mostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
9. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagula-tion quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005;3(5):955-961.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239.
11. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous throm-boembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893-900.
12. Carrier M, LE GG, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589.
13. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766-774.
14. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19): 1710-1716.
15. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320-328.
16. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010;8(11): 2436-2442.